May 23, 2017
2 min read
Save

Systemic β-blockers have little effect on IOP reduction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Nonselective systemic β-blocker intake showed a clinically relevant association and a borderline significant trend with IOP decrease, while the use of cardioselective β-blockers and all other cardiovascular medication did not, according to researchers.

Perspective from Derek MacDonald, OD, FAAO

In contrast to published literature, the researchers found no association between systemic β-blocker intake and lower IOP in non-glaucoma subjects, according to research in British Journal of Ophthalmology.

Researchers examined 13,527 adults taking cardiovascular medication from 35 years to 74 years from the Gutenberg Health Study.

The medication classes examined were peripheral vasodilators, diuretics, β-blockers, calcium channel blockers, renin-angiotensin blockers, nitrates, other antihypertensive medications, aspirin and statins.

IOP was measured using a noncontact tonometer (Nidek NT-2000, Nidek Co.).

Researchers found that both selective and nonselective systemic β-blocker intake were not associated with statistically significant lower IOP.

IOP was not associated with the use of ACE inhibitors after adjustment for body mass index, systolic blood pressure and central corneal thickness, according to researchers.

The highest mean IOP was observed in subjects taking other systemic antihypertensives. In addition, men on diuretics, nitrates or peripheral vasodilators had a lower mean IOP than men not taking these medications.

Only nonselective β-blockers, selective β-blockers and β-blockers in general showed a trend to be associated with lower IOPs, according to researchers.
β-blocker is used to treat IOP in a patient who is concomitantly given systemic β-blockers,” researchers wrote.

Researchers said that only a prospective randomized controlled study will determine a causal relationship between systemic β-blocker and IOP effect. – by Abigail Sutton

Disclosures: The researchers report no relevant financial disclosures.